Direkt zum Inhalt
Merck

GF43341634

Platin

wire reel, 0.1m, diameter 0.25mm, as drawn, 99.99+%

Synonym(e):

Platinum, PT005140

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

1 EA
CHF 252.00

CHF 252.00


Check Cart for Availability

Bulk-Bestellung anfordern

Größe auswählen

Ansicht ändern
1 EA
CHF 252.00

About This Item

Empirische Formel (Hill-System):
Pt
CAS-Nummer:
Molekulargewicht:
195.08
MDL-Nummer:
UNSPSC-Code:
12141734
PubChem Substanz-ID:
NACRES:
NA.23

CHF 252.00


Check Cart for Availability

Bulk-Bestellung anfordern

Assay

99.99%

Form

wire

Hersteller/Markenname

Goodfellow 433-416-34

Widerstandsfähigkeit

10.6 μΩ-cm, 20°C

L × Durchm.

0.1 m × 0.25 mm

bp

3827 °C (lit.)

mp (Schmelzpunkt)

1772 °C (lit.)

Dichte

21.45 g/cm3 (lit.)

SMILES String

[Pt]

InChI

1S/Pt

InChIKey

BASFCYQUMIYNBI-UHFFFAOYSA-N

Allgemeine Beschreibung

For updated SDS information please visit www.goodfellow.com.

Rechtliche Hinweise

Product of Goodfellow

Lagerklassenschlüssel

13 - Non Combustible Solids

WGK

nwg

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Himashinie V K Diyabalanage et al.
Cancer letters, 329(1), 1-8 (2012-10-04)
One of the most promising strategies to increase the efficacy of standard chemotherapy drugs is by combining them with low doses of histone deacetylases inhibitors (HDACis). Regarded as chemosensitizers, the addition of well-tolerated doses of HDACis to platinum-based chemotherapeutics has
Antonio González
Future oncology (London, England), 9(12 Suppl), 29-35 (2013-11-15)
Ovarian carcinoma is still one of the most common causes of death from cancer in the western world. Despite high sensitivity to chemotherapy, the majority of patients will relapse within 3 years. In this article the focus is centered on
Nicoletta Colombo
Future oncology (London, England), 9(12 Suppl), 19-23 (2013-11-15)
Ovarian cancer is the leading cause of gynecological cancer deaths worldwide. Despite primary treatment with platinum-containing regimens, the majority of women will experience recurrent disease and subsequent death. Recurrent ovarian cancer remains a challenge for successful management, and the choice
Hai-Bo Wei et al.
Chinese medical journal, 125(16), 2902-2907 (2012-08-31)
Platinum-based regimens are used as standard first-line chemotherapy in non-small cell lung cancer (NSCLC) patients. To study if pharmacogenetic approach may allow a tailored selection of platinum chemotherapy for advanced NSCLC, we performed a meta-analysis to compare chemosensitivity to platinum
Jianbo Wu et al.
Accounts of chemical research, 46(8), 1848-1857 (2013-07-03)
An efficient oxygen reduction reaction (ORR) offers the potential for clean energy generation in low-temperature, proton-exchange membrane fuel cells running on hydrogen fuel and air. In the past several years, researchers have developed high-performance electrocatalysts for the ORR to address

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.